Richard Scheller

23andMe’s chief scientific officer and former therapeutics foreman Richard Scheller has left his hands-on role at the sequencing company and landed on the boards of at least two biotechs—namely, two of the biggest money raisers of the year so far.

At BridgeBio, which recently went public and brought in nearly $350 million with its IPO, Scheller now holds the title of chairman of R&D, a vaguely defined and apparently part-time position.

Meanwhile, the genetics-focused Maze Therapeutics has also claimed him for a seat on its board of directors, following its February premiere with a $191 million series A round. Scheller will continue on as a board member of 23andMe, as well.

Richard Scheller is the Chief Science Officer and Head of Therapeutics at 23andMe, based in United States, North America. With a background in Biotechnology, Richard Scheller has a rich history of leadership and innovation. Richard Scheller studied Bachelor Biochemistry @ University of Wisconsin-Madison. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.